

## Monday 16 September 2024, 13:00-14:30 CEST

Valencia Auditorium, Hall 5, Fira Barcelona Gran Via, Barcelona, Spain

Please join us for an interesting and interactive discussion to explore how PI3K inhibitors can further personalise and optimise the treatment of patients with HR+ breast cancer.

We look forward to seeing you in Barcelona or via the live stream!



Dr Carlos Barrios
Hospital São Lucas,
PUCRS. Brazil



**Dr Kevin Kalinsky**Winship Cancer Institute of
Emory University, USA



**Dr Komal Jhaveri** Memorial Sloan Kettering Cancer Center, USA

Welcome	Dr Carlos Barrios
PI3K: Unmet need has driven a succession of targeting attempts	Dr Kevin Kalinsky
PI3Ki: Continued efforts are showing success	Dr Komal Jhaveri
PI3Ki: An evolving drug class with an exciting future	Dr Carlos Barrios
Q and A	All
Close	Dr Kevin Kalinsky